Skip to main content

Table 1 Baseline characteristics of the study population in derivation and validation cohorts

From: A neutrophil-to-lymphocyte ratio-based prognostic model to predict mortality in patients with HBV-related acute-on-chronic liver failure

Variable

Total(n = 494)

Derivationcohort (n = 290)

Validationcohort (n = 204)

Pvalue

Age (years)

45 (37–55)

44 (37–54)

46 (38–58)

0.172

Male,% (n/N)

85.2 (421/494)

86.9 (252/290)

82.8 (169/204)

0.211

HBeAg positive,% (n/N)

43.3 (214/494)

44.5 (129/290)

41.7 (85/204)

0.534

HBV DNA,% (n/N)

    

 ≤ 200 IU/ml

30.0 (148/494)

35.2 (102/290)

22.5 (46/204)

 < 0.001

 200–2 × 10 4 IU/ml

36.2 (179/494)

39.3 (114/290)

31.8 (65/204)

 

 ≥ 2 × 10 4 IU/ml

33.8 (167/494)

25.5 (74/290)

45.7 (93/204)

 

Cirrhosis,% (n/N)

77.1 (381/494)

76.9 (223/290)

77.5 (158/204)

0.885

Ascites,% (n/N)

66.2 (327/494)

65.2 (189/290)

67.6 (138/204)

0.567

Bacterial infection,% (n/N)

38.5 (190/494)

42.4 (123/290)

32.8 (67/204)

0.031

Laboratory test

    

 WBC (109 /L)

6.3 (4.7–9.1)

6.8 (5.0–9.8)

5.9 (4.4–8.1)

0.005

 NLR

4.3 (2.5–7.9)

4.6 (2.5–7.9)

4.1 (2.4–7.7)

0.272

 Platelets (109 /L)

90 (59–129)

90.5 (59–128)

90 (58.5–131)

0.871

 TB (mg/dL)

323 (205–467)

333 (209–467)

310 (201–467)

0.573

 Albumin (g/L)

32.4 ± 5.3

32.8 ± 5.2

31.7 ± 5.4

0.012

 Creatinine (µmol/L)

66 (54–81)

66 (56–81)

65 (53–82)

0.524

 Sodium (mmol/L)

137 (133–139)

136 (132–139)

137 (133–139)

0.079

 Glucose (mmol/L)

5.7 (4.4–7.8)

5.7 (4.4–7.5)

5.7 (4.1–8.5)

0.583

 Lactate (mmol/L)

1.9 (1.3–2.6)

2.0 (1.3–2.7)

1.8 (1.3–2.4)

0.238

 INR

1.9 (1.6–2.5)

2.1 (1.7–2.8)

1.8 (1.5–2.3)

 < 0.001

HE grade

0 (0–1)

0 (0–1)

0 (0–1)

0.360

Severity score

    

 CTP score

11 (10–12)

11 (10–12)

11 (10–12)

0.341

 MELD score

22 (18–27)

23 (19–28)

21 (18–25)

0.014

 MELD-Na score

23 (19–30)

24 (19–32)

22 (19–28)

0.014

 AARC ACLF score

9 (7–10)

9 (8–11)

8.5 (7–10)

0.002

  5–7

28.7 (142/494)

24.1 (70/290)

35.3 (72/204)

0.010

  8–10

47.0 (232/494)

47.9 (139/290)

45.6 (93/204)

 

  11–15

24.3 (120/494)

27.9 (81/290)

19.1 (39/204)

 

Antiviral history,% (n/N)

    

 Naïve

71.3 (352/494)

69.3 (201/290)

74.0 (151/204)

0.255

 Non–naïve

28.7 (142/494)

30.7 (89/290)

26.0 (53/204)

0.255

 Poor adherence

76.8 (109/142)

78.7 (70/89)

73.6 (39/53)

0.489

Antibiotic history,% (n/N)

36.4 (180/494)

41.0 (119/290)

29.9 (61/204)

0.011

Artificial liver support history,% (n/N)

19.2 (95/494)

21.0 (61/290)

16.7 (34/204)

0.225

  1. HBeAg hepatitis b envelope antigen, HBV hepatitis b virus, WBC white blood cell count, NLR neutrophil/lymphocyte ratio, TB total bilirubin, INR international normalized ratio, HE hepatic encephalopathy, CTP Child-Turcotte-Pugh, MELD model for end-stage liver disease, ACLF acute-on-chronic liver failure, AARC Asian Pacific Society for the Study of the Liver ACLF research consortium
  2. Continuous variables with normal distributions were described using mean ± SD. Continuous variables with skewed distributions were described using median with interquartile range (IQR) and compared using the Mann–Whitney U test. Categorical variables were expressed as percentages (frequencies) and compared using the Chi‐square test followed by Fisher’s exact test, as appropriate
Back to article page

BMC Gastroenterology

ISSN: 1471-230X

Contact us